Last reviewed · How we verify
Androgen Hormonal Suppression and Radiation
This combination therapy suppresses androgen signaling in prostate cancer cells while using radiation to directly damage tumor DNA and kill cancer cells.
This combination therapy suppresses androgen signaling in prostate cancer cells while using radiation to directly damage tumor DNA and kill cancer cells. Used for Locally advanced or high-risk prostate cancer (in combination with external beam radiation therapy).
At a glance
| Generic name | Androgen Hormonal Suppression and Radiation |
|---|---|
| Sponsor | Dana-Farber Cancer Institute |
| Drug class | Androgen deprivation therapy (combination with radiation) |
| Target | Androgen receptor pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Androgen deprivation therapy (ADT) blocks testosterone production or androgen receptor signaling, which slows growth of androgen-dependent prostate cancer. Concurrent radiation therapy delivers high-energy beams to the tumor site to cause direct DNA damage and cell death. The combination aims to improve local control and overall survival in advanced prostate cancer by targeting both hormonal dependence and tumor burden.
Approved indications
- Locally advanced or high-risk prostate cancer (in combination with external beam radiation therapy)
Common side effects
- Hot flashes
- Erectile dysfunction
- Fatigue
- Bowel toxicity (diarrhea, rectal irritation)
- Urinary symptoms (frequency, urgency)
- Gynecomastia
- Decreased libido
Key clinical trials
- Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer (PHASE1)
- Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer (PHASE3)
- Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer (PHASE3)
- Study to Monitor the Effects of Androgen Suppression Treatment on the Heart (PHASE4)
- Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: